Comparing SG&A Expenses: Cytokinetics, Incorporated vs Rhythm Pharmaceuticals, Inc. Trends and Insights

Biotech Giants' SG&A Expenses: A Decade of Growth and Strategy

__timestampCytokinetics, IncorporatedRhythm Pharmaceuticals, Inc.
Wednesday, January 1, 2014172680001213000
Thursday, January 1, 2015196670003425000
Friday, January 1, 2016278230006311000
Sunday, January 1, 2017364680009518000
Monday, January 1, 20183128200028080000
Tuesday, January 1, 20193961000036550000
Wednesday, January 1, 20205282000046125000
Friday, January 1, 20219680300068486000
Saturday, January 1, 202217797700092032000
Sunday, January 1, 2023173612000117532000
Loading chart...

Igniting the spark of knowledge

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing operational costs is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Cytokinetics, Incorporated and Rhythm Pharmaceuticals, Inc. over a decade, from 2014 to 2023. Cytokinetics has seen a staggering increase in SG&A expenses, growing by over 900% from 2014 to 2022, peaking at approximately $178 million in 2022. Meanwhile, Rhythm Pharmaceuticals, although starting with lower expenses, has also experienced significant growth, with a nearly 100-fold increase, reaching around $117 million in 2023. This trend highlights the escalating costs associated with scaling operations and advancing drug development. As both companies continue to innovate, understanding these financial dynamics offers valuable insights into their strategic priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025